864 related articles for article (PubMed ID: 15735047)
21. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
[TBL] [Abstract][Full Text] [Related]
22. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
Frankel TL; Burns WR; Peng PD; Yu Z; Chinnasamy D; Wargo JA; Zheng Z; Restifo NP; Rosenberg SA; Morgan RA
J Immunol; 2010 Jun; 184(11):5988-98. PubMed ID: 20427771
[TBL] [Abstract][Full Text] [Related]
23. MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design.
Zeng G
J Immunother; 2001; 24(3):195-204. PubMed ID: 11394496
[TBL] [Abstract][Full Text] [Related]
24. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
Leisegang M; Turqueti-Neves A; Engels B; Blankenstein T; Schendel DJ; Uckert W; Noessner E
Clin Cancer Res; 2010 Apr; 16(8):2333-43. PubMed ID: 20371691
[TBL] [Abstract][Full Text] [Related]
25. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376.
Valmori D; Pittet MJ; Vonarbourg C; Rimoldi D; Liénard D; Speiser D; Dunbar R; Cerundolo V; Cerottini JC; Romero P
Cancer Res; 1999 Aug; 59(16):4050-5. PubMed ID: 10463606
[TBL] [Abstract][Full Text] [Related]
26. Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity.
van der Veken LT; Hagedoorn RS; van Loenen MM; Willemze R; Falkenburg JH; Heemskerk MH
Cancer Res; 2006 Mar; 66(6):3331-7. PubMed ID: 16540688
[TBL] [Abstract][Full Text] [Related]
27. Rapid alphabeta TCR-mediated responses in gammadelta T cells transduced with cancer-specific TCR genes.
Hiasa A; Nishikawa H; Hirayama M; Kitano S; Okamoto S; Chono H; Yu SS; Mineno J; Tanaka Y; Minato N; Kato I; Shiku H
Gene Ther; 2009 May; 16(5):620-8. PubMed ID: 19242528
[TBL] [Abstract][Full Text] [Related]
28. Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation.
Wankowicz-Kalinska A; Mailliard RB; Olson K; Graham F; Edington H; Kirkwood JM; Martinek S; Das PK; Storkus WJ
Melanoma Res; 2006 Apr; 16(2):165-74. PubMed ID: 16567972
[TBL] [Abstract][Full Text] [Related]
29. A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes.
Willemsen RA; Debets R; Hart E; Hoogenboom HR; Bolhuis RL; Chames P
Gene Ther; 2001 Nov; 8(21):1601-8. PubMed ID: 11894998
[TBL] [Abstract][Full Text] [Related]
30. Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy.
Godet Y; Desfrançois J; Vignard V; Schadendorf D; Khammari A; Dreno B; Jotereau F; Labarrière N
Eur J Immunol; 2010 Jun; 40(6):1786-94. PubMed ID: 20217862
[TBL] [Abstract][Full Text] [Related]
31. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
[TBL] [Abstract][Full Text] [Related]
32. IL-2 gene-transduced human HLA-A2 melanoma cells can generate a specific antitumor cytotoxic T-lymphocyte response.
Guarini A; Gansbacher B; Cronin K; Fierro MT; Foa R
Cytokines Mol Ther; 1995 Mar; 1(1):57-64. PubMed ID: 9384664
[TBL] [Abstract][Full Text] [Related]
33. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
[TBL] [Abstract][Full Text] [Related]
34. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
35. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
Rowe HM; Lopes L; Ikeda Y; Bailey R; Barde I; Zenke M; Chain BM; Collins MK
Mol Ther; 2006 Feb; 13(2):310-9. PubMed ID: 16275163
[TBL] [Abstract][Full Text] [Related]
36. Retargeting of a T cell line by anti MAGE-3/HLA-A2 alpha beta TCR gene transfer.
Calogero A; Hospers GA; Krüse KM; Schrier PI; Mulder NH; Hooijberg E; de Leij LF
Anticancer Res; 2000; 20(3A):1793-9. PubMed ID: 10928109
[TBL] [Abstract][Full Text] [Related]
37. Cytolytic T-cell clones define HLA-A2-restricted human cutaneous melanoma peptide epitopes: correlation with T-cell receptor usage.
Maeurer MJ; Hurd S; Martin DM; Storkus WJ; Lotze MT
Cancer J Sci Am; 1995; 1(2):162-70. PubMed ID: 9166469
[TBL] [Abstract][Full Text] [Related]
38. Emergence of regulatory CD4+ T cell response to repetitive stimulation with antigen-presenting cells in vitro: implications in designing antigen-presenting cell-based tumor vaccines.
Chakraborty NG; Li L; Sporn JR; Kurtzman SH; Ergin MT; Mukherji B
J Immunol; 1999 May; 162(9):5576-83. PubMed ID: 10228040
[TBL] [Abstract][Full Text] [Related]
39. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
Morgan RA; Dudley ME; Yu YY; Zheng Z; Robbins PF; Theoret MR; Wunderlich JR; Hughes MS; Restifo NP; Rosenberg SA
J Immunol; 2003 Sep; 171(6):3287-95. PubMed ID: 12960359
[TBL] [Abstract][Full Text] [Related]
40. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.
Lapointe R; Bellemare-Pelletier A; Housseau F; Thibodeau J; Hwu P
Cancer Res; 2003 Jun; 63(11):2836-43. PubMed ID: 12782589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
